Newsroom | 1581 results

WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal transition for the company, supported by a robust pipeline that includes two clinical-stage assets, one of which is IGT-427 (now called MK-8748), an investigational bi-specific antibody (Anti-VEGF/TIE2), for p...

BOSTON--(BUSINESS WIRE)--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem....

LUGANO, Schweiz--(BUSINESS WIRE)--Da das wissenschaftliche Interesse an lichtbasierter Stimulation, neuroendokriner Regulation und integrativer Medizin international weiter zunimmt, hat das Switzerland Eye Research Institute (SERI Lugano) eine neue internationale wissenschaftliche Outreach-Initiative ins Leben gerufen, die sich auf die Einbindung der Öffentlichkeit und die interdisziplinäre Forschungskommunikation in den Bereichen Neurowissenschaften und zelluläre Modulation konzentriert. Die I...

LUGANO, Suisse--(BUSINESS WIRE)--Alors que l’intérêt scientifique porté à la stimulation par la lumière, à la régulation neuroendocrinienne et à la médecine intégrative ne cesse de croître à l’échelle internationale, le Switzerland Eye Research Institute (SERI, Lugano) vient de lancer une nouvelle initiative scientifique internationale visant à favoriser l’engagement du public et la communication interdisciplinaire dans les domaines des neurosciences et de la modulation cellulaire. L'initiative...

DURHAM, N.C.--(BUSINESS WIRE)--Lexitas Pharma Services, a portfolio company of QHP Capital, is pleased to announce the closing of its acquisition of Erie Retina Research—one of the nation’s premier retina research centers led by Dr. David Almeida, MD, MBA, PhD—which will operate as a wholly owned subsidiary of Lexitas. As part of the transaction, Lexitas also acquired CASExERIE, LLC, an ophthalmic innovation hub specializing in advanced research, surgical training, and retina-focused product de...

LUGANO, Switzerland--(BUSINESS WIRE)--SERI Lugano Launches International Scientific Outreach Initiative on Light-Based Neuroscience and Pineal Gland Research...

WOODBRIDGE, Conn.--(BUSINESS WIRE)--LambdaVision, a pre-clinical-stage biotech advancing on-Earth and microgravity bioprocesses, today announced a strategic partnership with Helogen Corporation to launch a joint orbital manufacturing mission of LambdaVision’s artificial retina protein aboard Helogen’s fully autonomous manufacturing system in low-Earth orbit. The mission is targeted for launch in the second half of 2026. As this planned mission will mark LambdaVision’s first flight outside of th...

BOSTON & PHILADELPHIA--(BUSINESS WIRE)--Ontada, a McKesson business dedicated to real-world oncology data and insights, will present new research and introduce ON.Journey at ISPOR 2026....

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--PRISM Vision Group announced that it closed a transaction with Retina Macula Institute, through which RMI joins its network of affiliated practices....

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “This quarter, we continued to build on our developmental and clinical acc...